The present invention provides novel antigens of an allergy to egg, methods and kits for diagnosing an allergy to egg, pharmaceutical compositions comprising such an antigen, eggs or processed products of egg in which such an antigen is eliminated or reduced, birds that deliver such eggs or are born from such eggs, a method for producing processed products of egg in which such an antigen is eliminated or reduced, and a tester for determining the presence or absence of an egg antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an antigen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and raw materials or processed products in which an antigen comprising such a polypeptide is eliminated or reduced. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

A method assaying the levels of expression Apolipoprotein AI, Apolipoprotein AII, E-Cadherin, and Galectin-3 in a biological sample from a person having or suspected of having colorectal cancer. The sample is remote from any tumor.

Provided herein are methods for determining the ratio of one or more isoforms of a protein in a sample.

The present disclosure provides methods of identifying a candidate agent for treating an apoE-associated neurodegenerative disorder. The methods involve contacting a PCSK1 or a PCSK2 polypeptide with an apolipoprotein E polypeptide in the presence of a test agent.

Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.

This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.

Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human ApoE protein. In some embodiments the polypeptide comprises ApoE2. In some embodiments the polypeptide comprises ApoE3. In some embodiments the polypeptide comprises ApoE4. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress Apo-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease. Also disclosed are methods of screening yeast cells to identify genetic suppressors or enhancers of ApoE-induced toxicity. Also disclosed are genetic suppressors or enhancers of ApoE-induced toxicity identified using the methods, and human homologs thereof. Also disclosed are methods of identifying compounds that modulate expression or activity of genetic modifiers of ApoE-induced toxicity.

Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.

Provided herein are compositions, systems, kits, and methods for detecting cardiovascular disease, risk of cardiovascular disease, and/or reverse cholesterol transport potential in a subject based on the levels of PIP2 phospholipid in the subject.

Methods and compositions related to lipoproteins reactions are provided. Particularly, quantitation of lipoprotein subgroup particle numbers may be used to detect lipoprotein's response to oxidation conditions and incubation conditions. In further aspects, ultracentrifugation may be improved to analyze the lipoprotein profiles. Embodiments are directed to methods for generating a oxidation susceptibility measure for serum lipoproteins. In certain aspects a first portion of a serum sample is used to generate a base lipid particle profile (LPP) and a second portion of the serum sample is used to generate an oxidized lipid particle profile.